NASDAQ · ZYBT

Zhengye Biotechnology Holding Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$1.59

Up+$0.02 (+1.27%)

Updated Sep 11, 2026, 12:08 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 94.78M
P/E ratio: 0
Dividend yield: 0.00%
52-week range: $0.62 – $8.01
Volume: 45.96K
Avg. volume: 423.1K

Price performance

ZYBT price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

Market data is busy. Please try again shortly.

Latest ZYBT news

The latest Smart Investors Daily articles mentioning ZYBT.

No results

No recent SID articles mention ZYBT.

Latest ZYBT news

The latest Smart Investors Daily articles mentioning ZYBT.

Stock researchCompany · Overview

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

ZYBT research

Overview

Company profile and research snapshot.

Company profile

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus: —
Average target: —
Implied upside: —
Analysts: —

Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 6, 2026

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that on August 5, 2026, the Company received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with th

Benzinga · Aug 6, 2026

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By